Advances in Immunotherapy for Glioblastoma Multiforme

Joint Authors

Jian, Zhihong
Stary, Creed M.
Xiong, Xiaoxing
Ye, Baixin
Gu, Lijuan
Huang, Boyuan
Zhang, Hongbo

Source

Journal of Immunology Research

Issue

Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-11, 11 p.

Publisher

Hindawi Publishing Corporation

Publication Date

2017-02-19

Country of Publication

Egypt

No. of Pages

11

Main Subjects

Biology

Abstract EN

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults.

Patients with GBM have poor outcomes, even with the current gold-standard first-line treatment: maximal safe resection combined with radiotherapy and temozolomide chemotherapy.

Accumulating evidence suggests that advances in antigen-specific cancer vaccines and immune checkpoint blockade in other advanced tumors may provide an appealing promise for immunotherapy in glioma.

The future of therapy for GBM will likely incorporate a combinatorial, personalized approach, including current conventional treatments, active immunotherapeutics, plus agents targeting immunosuppressive checkpoints.

American Psychological Association (APA)

Huang, Boyuan& Zhang, Hongbo& Gu, Lijuan& Ye, Baixin& Jian, Zhihong& Stary, Creed M.…[et al.]. 2017. Advances in Immunotherapy for Glioblastoma Multiforme. Journal of Immunology Research،Vol. 2017, no. 2017, pp.1-11.
https://search.emarefa.net/detail/BIM-1181728

Modern Language Association (MLA)

Huang, Boyuan…[et al.]. Advances in Immunotherapy for Glioblastoma Multiforme. Journal of Immunology Research No. 2017 (2017), pp.1-11.
https://search.emarefa.net/detail/BIM-1181728

American Medical Association (AMA)

Huang, Boyuan& Zhang, Hongbo& Gu, Lijuan& Ye, Baixin& Jian, Zhihong& Stary, Creed M.…[et al.]. Advances in Immunotherapy for Glioblastoma Multiforme. Journal of Immunology Research. 2017. Vol. 2017, no. 2017, pp.1-11.
https://search.emarefa.net/detail/BIM-1181728

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references

Record ID

BIM-1181728